Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in serious chronic disease treatment.

Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.

Jan 8, 2025 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.

In some cases, healthcare professionals and patients can visit local Novo Nordisk websites to find out more about our medicines. Please note that in some countries we are not allowed to …

Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial. Bagsværd, …

Dec 20, 2024 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, …

1 day ago · Novo Nordisk Executive Management and other members of senior management provided a full review of our strategy, operations and financial targets. Download the …

Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or …

Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or …